Maven Diagnostic

Maven Diagnostic is a private healthcare diagnostics company developing and deploying high-sensitivity point-of-care assays for infectious diseases and selected immune-monitoring applications. Its platform combines rare-earth doped nanocrystal reporters, proprietary optical detection, and lateral flow assay formats to deliver quantitative results from saliva, finger-prick blood, and swab samples. The company highlights field use of its technology at global scale, with more than 5 million point-of-care tests deployed across Africa, Asia, and South America. Maven's portfolio includes demonstrated assays for tuberculosis, leprosy, schistosomiasis, neurocysticercosis, and biomarker-based monitoring such as infliximab/anti-TNFalpha and IL-6, while additional programs including SARS-CoV-2, Ebola, anthrax, and complement-related monitoring are in development or field trials. The company appears focused on low-resource and global-health settings and collaborates with organizations including the Gates Foundation, CDC, and Leiden University.